Krystal Biotech price target raised to $175 from $130 at Guggenheim

Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Krystal Biotech to $175 from $130 and keeps a Buy rating on the shares. For an annuity that could generate in excess of $500M in free cash flow, prior to factoring in growth from the ophthalmic opportunity and the “de minimis impact” of pipeline initiatives, the firm contends that the business “could be valued at $5B+,” the analyst tells investors following what the firm describes as “an in-line quarter on revenue has translated into an outsized move in the shares.”